4D MOLECULAR THERAPEUTICS IN's ticker is FDMT and the CUSIP is 35104E100. A total of 113 filers reported holding 4D MOLECULAR THERAPEUTICS IN in Q4 2023. The put-call ratio across all filers is 2.72 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $1,000 | -34.4% | 47,646 | -0.4% | 0.00% | -100.0% |
| Q1 2024 | $1,524 | -30.8% | 47,819 | -56.0% | 0.00% | 0.0% |
| Q4 2023 | $2,202 | +134.0% | 108,709 | +47.0% | 0.00% | 0.0% |
| Q3 2023 | $941 | -63.4% | 73,935 | -48.1% | 0.00% | -50.0% |
| Q2 2023 | $2,574 | +161.6% | 142,464 | +148.9% | 0.00% | – |
| Q1 2023 | $984 | +27.8% | 57,229 | +65.1% | 0.00% | – |
| Q4 2022 | $770 | -99.2% | 34,673 | +204.8% | 0.00% | – |
| Q3 2022 | $91,000 | +33.8% | 11,376 | +18.3% | 0.00% | – |
| Q2 2022 | $68,000 | -62.4% | 9,616 | -19.6% | 0.00% | – |
| Q1 2022 | $181,000 | – | 11,956 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| VR Adviser, LLC | 4,400,000 | $92,356,000 | 5.88% |
| Deep Track Capital, LP | 4,061,401 | $85,248,807 | 2.54% |
| BVF INC/IL | 3,922,413 | $82,331,449 | 2.31% |
| Decheng Capital LLC | 347,835 | $7,301,057 | 2.24% |
| Novo Holdings A/S | 1,400,000 | $29,386,000 | 1.71% |
| Eagle Health Investments LP | 462,911 | $9,716,502 | 1.70% |
| Opaleye Management Inc. | 345,750 | $7,257,293 | 1.66% |
| RA Capital Management | 5,098,211 | $107,011,449 | 1.42% |
| Redmile Group, LLC | 1,073,435 | $22,531,401 | 1.36% |
| Casdin Capital, LLC | 800,000 | $16,792,000 | 1.29% |